Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - Supernus Pharmaceuticals reported $211.57 million in revenue for Q4 2025, marking a 21.5% year-over-year increase and exceeding the Zacks Consensus Estimate by 7.57% [1] - The company's EPS for the same quarter was $0.92, a significant increase from $0.75 a year ago, resulting in an EPS surprise of 228.57% compared to the consensus estimate of $0.28 [1] Revenue Performance - Trokendi XR generated $8.4 million in net product sales, below the average estimate of $5.81 million, reflecting a year-over-year decline of 43.2% [4] - Oxtellar XR reported $6.8 million in net product sales, surpassing the average estimate of $5.75 million, but showing a year-over-year decrease of 48.5% [4] - APOKYN achieved $9.6 million in net product sales, slightly below the average estimate of $9.93 million, with a year-over-year decline of 52.2% [4] - Qelbree's net product sales were $81 million, below the average estimate of $87.72 million, but showing an 8.9% year-over-year increase [4] - Collaboration revenue from ZURZUVAE was $32.8 million, exceeding the average estimate of $28.05 million [4] - Total net product sales amounted to $158.1 million, below the average estimate of $193.42 million, representing a year-over-year decline of 5% [4] - Royalty, licensing, and other revenues reached $20.7 million, significantly above the average estimate of $3.25 million, with a year-over-year increase of 166.6% [4] - ONAPGO net product sales were $8.9 million, exceeding the average estimate of $6.1 million [4] - GOCOVRI generated $38.6 million in net product sales, slightly below the average estimate of $42.64 million, with a year-over-year increase of 4.6% [4] Stock Performance - Supernus shares have returned +3.1% over the past month, contrasting with a -1% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 5 (Strong Sell), indicating potential underperformance relative to the broader market in the near term [3]